BELLEVUE, Wash.– Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or “Novo”), pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem with multiple patient and consumer touchpoints for services and product innovation, today announced that its wholly owned subsidiary, Novo Healthnet Limited, has been granted a Natural Product Number (NPN) by Health Canada for its IoNovo for Kids pure iodine oral spray branded product line. An NPN is a product license assessed and granted by Health Canada Natural Health Products determined to be safe, effective, of high quality, and eligible for sale in Canada.
Robert Mattacchione, Novo’s CEO and Board Chairman, commented, “For decades, the global medical community has recognized Iodine as an aid for a healthy metabolism as well as one of nature’s finest killers in the microbial world. Our IoNovo Iodine for Kids product is an aqueous iodine dosed in a safe ingestible form, as a simple oral spray, for maximum bio-availability. Understanding children are highly mobile and social exposing them to harmful pathogens from the microbial world, we designed IoNovo for Kids, specifically for children under 13 years of age, to deliver micro-dose amounts per application. For the first time the child and their parents can simply spray iodine throughout the day providing a next level of personal biosecurity.”
Novo Integrated Sciences, Inc. is pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of multiple patient and consumer touchpoints for services and product innovation. Novo offers an essential and differentiated solution to deliver, or intend to deliver, these services and products through the integration of medical technology, advanced therapeutics, and rehabilitative science.
We believe that “decentralizing” healthcare, through the integration of medical technology and interconnectivity, is an essential solution to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered both now and in the future. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient’s home and away from on-site visits to primary medical centers with mass-services. This acceleration of “ease-of-access” in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective healthcare distribution.
